Startups
Chardan is an independent global investment bank specializing in SPACs, healthcare, and disruptive innovation spanning all sectors. Our range of services include capital raising, merger and acquisition advisory, strategic advisory, equity research, corporate access and institutional trading. Headquartered in New York City, Chardan is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: FINRA, SIPC, NASDAQ and the NYSE Arca, Inc. Disclaimer: Information posted on this Web site is believed to be reliable at the time of posting; Chardan Capital Markets, LLC and its affiliates cannot, however, guarantee the accuracy or completeness of such information or make any warranties with regard to the results to be obtained from its use. Information on this Web site is not intended to provide financial, legal, accounting or tax advice and should not be relied upon in that regard. Chardan Capital Markets, LLC and its affiliates are not responsible in any manner for direct, indirect, special or consequential damages howsoever caused, arising out of the use of this Web site or any of its content.
Overview
Location
United States, New York
Employees
51-200
Founded date
2002
Mentions in press and media 15
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 16, 2025 | Japan Go IPO Summit Announces Roster of Expert Speakers for Event June 5th in Tokyo | Kura Sushi Executive to Deliver Keynote Address on Elements of Success for Cross-Border Listings TOKYO and NEW YORK, April 16, 2025 /PRNewswire/ -- The Japan Go IPO Summit, co-hosted by Nasdaq and MarcumAsia, is proud to announce an excepti... |
| Sep 5, 2024 | Laverock Therapeutics announces forthcoming investor, scientific and partnering conference schedule | STEVENAGE, United Kingdom, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced therapies to tackle major diseases, today announc... |
| Feb 27, 2024 | Chardan Acts as Financial Advisor in SPAC Takeover | NEW YORK, Feb. 27, 2024 /PRNewswire/ -- Chardan, a global investment bank, has announced that it has acted as financial advisor to Blufire Capital in connection with the Purchase and Sponsor Handover Agreement between Blufire Capital and Ev... |
| Feb 6, 2023 | Southeast Asia SPAC Conference Provides Roadmap for Corporates from the Region Seeking to List on U.S. Stock Markets | SINGAPORE, Feb. 6, 2023 /PRNewswire/ -- Corporate management teams, private equity firms, and key advisors will get a comprehensive update on the state of the SPAC market at the Southeast Asia SPAC Conference on "Alternative paths to p... |
| Aug 10, 2021 | Chardan : Co-Sponsors and Acts as Sole Bookrunner in CleanTech Acquisition Corp.'s $172.5 Million IPO | NEW YORK, Aug. 10, 2021 /PRNewswire/ -- Chardan, a global investment bank with a leading SPAC practice, today announced that it acted as both co-sponsor and sole bookrunner in the $172.5 million IPO of CleanTech Acquisition Corp. (NASDAQ: C... |
| Aug 2, 2021 | Chardan Expands Equity Research Team | NEW YORK, Aug. 2, 2021 /PRNewswire/ -- Chardan, an independent global investment bank specializing in healthcare, technology, SPACs and emerging growth companies, announced today that Brian Dobson has joined the firm as a Senior Research An... |
| Aug 2, 2021 | Chardan : Expands Equity Research Team | NEW YORK, Aug. 2, 2021 /PRNewswire/ -- Chardan, an independent global investment bank specializing in healthcare, technology, SPACs and emerging growth companies, announced today that Brian Dobson has joined the firm as a Senior Research An... |
| Jul 12, 2021 | Chardan : Names Gbola Amusa, MD, CFA Chief Scientific Officer | NEW YORK, July 12, 2021 /PRNewswire/ -- Chardan, a global investment bank with a leading disruptive biotech practice, today announced that Gbola Amusa, MD, CFA has been appointed Chief Scientific Officer. Dr. Amusa will retain the title of ... |
| Jun 21, 2021 | FEMASYS INC. Chardan : Acts as Lead Left Bookrunner in Femasys' $34.45 Million IPO | NEW YORK, June 21, 2021 /PRNewswire/ -- Chardan, a global investment bank, today announced that it acted as lead left bookrunner in the successful closing of the $34.45 million IPO of Femasys, Inc. (NASDAQ: FEMY) a biomedical company focuse... |
Show more
Reviews 0
FAQ about Chardan
When was Chardan founded?
Chardan was founded in 2002.
What has the press written about Chardan?
Parsers VC has collected 15 articles mentioning Chardan, among them “Japan Go IPO Summit Announces Roster of Expert Speakers for Event June 5th in Tokyo” (Apr 16, 2025) and “Laverock Therapeutics announces forthcoming investor, scientific and partnering conference schedule” (Sep 5, 2024).
Is Chardan still active?
Yes, Chardan is active; its latest activity on Parsers VC dates from Jun 13, 2025.